Clinical Trial Detail

NCT ID NCT03901378
Title Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ochsner Health System
Indications

gastrointestinal neuroendocrine tumor

large cell neuroendocrine carcinoma

pancreatic endocrine carcinoma

Therapies

Carboplatin + Etoposide + Pembrolizumab

Pembrolizumab

Cisplatin + Etoposide + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.